We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.88%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.74B
AUM Growth
+$366M
Cap. Flow
+$279M
Cap. Flow %
10.2%
Top 10 Hldgs %
49.25%
Holding
82
New
4
Increased
18
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$84.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$63.4M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$54M
4
RVMD icon
Revolution Medicines
RVMD
+$41.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$41.1M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$47.6M
2
CGEM icon
Cullinan Oncology
CGEM
+$47.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$34.3M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$21.2M
5
ANNX icon
Annexon
ANNX
+$19.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
26
DELISTED
Centessa Pharmaceuticals
CNTA
$36.3M 1.33%
9,423,215
+2,528,870
+37% +$9.25M
IDYA icon
27
IDEAYA Biosciences
IDYA
$3.44B
$33.7M 1.23%
2,455,089
+250,000
+11% +$4.17M
CGEM icon
28
Cullinan Oncology
CGEM
$1.01B
$32.7M 1.2%
3,196,701
-4,312,358
-57% -$47.5M
RAIN
29
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$30.8M 1.13%
3,526,729
– –
ETNB
30
DELISTED
89bio
ETNB
$28.1M 1.03%
+1,846,154
New +$24.1M
ACRS icon
31
Aclaris Therapeutics
ACRS
$716M
$27.2M 0.99%
3,360,941
+84,398
+3% +$1.07M
ALLK
32
DELISTED
Allakos
ALLK
$27M 0.99%
6,060,247
+1,053,326
+21% +$6.74M
OLMA icon
33
Olema Pharmaceuticals
OLMA
$1.01B
$26.4M 0.97%
7,611,503
– –
EPIX
34
DELISTED
ESSA Pharma
EPIX
$26M 0.95%
8,748,629
– –
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
$24.6M 0.9%
1,810,835
– –
NAMS icon
36
NewAmsterdam Pharma
NAMS
$3.24B
$20.5M 0.75%
1,521,948
– –
JANX icon
37
Janux Therapeutics
JANX
$920M
$19.2M 0.7%
1,585,677
+115,343
+8% +$1.92M
THRD
38
DELISTED
Third Harmonic Bio
THRD
$18M 0.66%
4,365,933
– –
CALT
39
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$18M 0.66%
750,000
– –
JSPR icon
40
Jasper Therapeutics
JSPR
$18.9M
$17.9M 0.66%
+990,000
New +$18.3M
VIGL
41
DELISTED
Vigil Neuroscience
VIGL
$17.8M 0.65%
1,813,633
– –
OVID icon
42
Ovid Therapeutics
OVID
$420M
$17.7M 0.65%
6,851,051
– –
ACIU icon
43
AC Immune
ACIU
$227M
$17.4M 0.64%
7,428,379
– –
STRO icon
44
Sutro Biopharma
STRO
$403M
$15.5M 0.57%
334,795
– –
ANTX icon
45
AN2 Therapeutics
ANTX
$195M
$15.4M 0.56%
1,563,963
– –
CBIO
46
Crescent Biopharma
CBIO
$526M
$12M 0.44%
95,443
– –
IMA
47
ImageneBio Inc
IMA
$63.6M
$10.9M 0.4%
264,097
+55,508
+27% +$2.55M
CTMX icon
48
CytomX Therapeutics
CTMX
$686M
$9.96M 0.36%
6,595,801
– –
ARAV
49
DELISTED
Aravive, Inc. Common Stock
ARAV
$9.57M 0.35%
4,784,214
– –
VERV
50
DELISTED
Verve Therapeutics
VERV
$9.37M 0.34%
650,000
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2023 Portfolio in Review

As of Q1 2023, BVF Inc held 82 positions worth $2.74B, up 15% from $2.37B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

BVF Inc deployed $279M of net new capital in Q1 2023, opening 4 new positions and adding to 18 existing holdings. Its largest new stake was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $47.5M trimmed.

  • BVF Inc's largest Q1 2023 buy was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.
  • BVF Inc added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2023, an estimated $84.9M increase.
  • BVF Inc's biggest Q1 2023 reduction was Cullinan Oncology, cutting an estimated $47.5M.
  • BVF Inc fully exited Arcus Biosciences in Q1 2023, selling an estimated $47.6M.
  • BVF Inc's ten largest holdings make up 49% of its $2.74B portfolio in Q1 2023.
  • BVF Inc opened 4 new positions and closed 10 in Q1 2023.
  • BVF Inc's portfolio value rose 15% quarter-over-quarter to $2.74B.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.